Hexose-6-phosphate Dehydrogenase Knock-out Mice Lack 11β-Hydroxysteroid Dehydrogenase Type 1-mediated Glucocorticoid Generation

Gareth G. Lavery, Elizabeth A. Walker, Nicole Draper, Pancharatnam Jeyasuria, Josep Marcos, Cedric Shackleton, Keith L. Parker, Perrin C. White, Paul M. Stewart

Journal of Biological Chemistry · 2005 · 207 citations · 27 references

DOIFull text

Open access

Concepts

Abstract

The local generation of active glucocorticoid by NADPH-dependent, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) oxoreductase activity, has emerged as an important factor in regulating hepatic glucose output and visceral adiposity. We have proposed that this NADPH is generated within the endoplasmic reticulum by the enzyme hexose-6-phosphate dehydrogenase. To address this hypothesis, we generated mice with a targeted inactivation of the H6PD gene. These mice were unable to convert 11-dehydrocorticosterone (11-DHC) to corticosterone but demonstrated increased corticosterone to 11-DHC conversion consistent with lack of 11β-HSD1 oxoreductase and a concomitant increase in dehydrogenase activity. This increased corticosterone clearance in the knock-out mice resulted in a reduction in circulating corticosterone levels. Our studies define the critical requirement of hexose-6-phosphate dehydrogenase for 11β-HSD1 oxoreductase activity and add a new dimension to the investigation of 11β-HSD1 as a therapeutic target in patients with the metabolic syndrome. The local generation of active glucocorticoid by NADPH-dependent, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) oxoreductase activity, has emerged as an important factor in regulating hepatic glucose output and visceral adiposity. We have proposed that this NADPH is generated within the endoplasmic reticulum by the enzyme hexose-6-phosphate dehydrogenase. To address this hypothesis, we generated mice with a targeted inactivation of the H6PD gene. These mice were unable to convert 11-dehydrocorticosterone (11-DHC) to corticosterone but demonstrated increased corticosterone to 11-DHC conversion consistent with lack of 11β-HSD1 oxoreductase and a concomitant increase in dehydrogenase activity. This increased corticosterone clearance in the knock-out mice resulted in a reduction in circulating corticosterone levels. Our studies define the critical requirement of hexose-6-phosphate dehydrogenase for 11β-HSD1 oxoreductase activity and add a new dimension to the investigation of 11β-HSD1 as a therapeutic target in patients with the metabolic syndrome. Corticosteroid hormone action is modulated in a tissue-specific fashion by the expression and activity of two isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD) 3The abbreviations used are: 11β-HSD, 11β-hydroxysteroid dehydrogenase; Hex-6-PDH, hexose-6-phosphate dehydrogenase; 11-DHC, 11-dehydrocorticosterone; KO, knock-out; WT, wild type; Glc-6-P, glucose 6-phosphate; ER, endoplasmic reticulum; MOPS, 4-morpholinepropanesulfonic acid; GC/MS, gas chromatography-mass spectrometry.3The abbreviations used are: 11β-HSD, 11β-hydroxysteroid dehydrogenase; Hex-6-PDH, hexose-6-phosphate dehydrogenase; 11-DHC, 11-dehydrocorticosterone; KO, knock-out; WT, wild type; Glc-6-P, glucose 6-phosphate; ER, endoplasmic reticulum; MOPS, 4-morpholinepropanesulfonic acid; GC/MS, gas chromatography-mass spectrometry. that interconvert hormonally active cortisol (or corticosterone in rodents) to their inactive derivatives, cortisone/11-dehydrocorticosterone (11-DHC) (1Tomlinson J.W. Walker E.A. Bujalska I.J. Draper N. Lavery G.G. Cooper M.S. Hewison M. Stewart P.M. Endocr. Rev. 2004; 25: 831-866Crossref PubMed Scopus (841) Google Scholar). 11β-HSD2 acts as a NAD-dependent dehydrogenase, inactivating glucocorticoids and protecting the mineralocorticoid receptor from illegitimate activation by cortisol in mineralocorticoid receptor-rich tissues such as the kidney and colon (2White P.C. Mune T. Agarwal A.K. Endocr. Rev. 1997; 18: 135-156Crossref PubMed Scopus (542) Google Scholar). By contrast, 11β-HSD1 is a bidirectional enzyme expressed in liver and adipose tissue. It catalyzes both oxidation and oxoreduction of glucocorticoids but acts in vivo predominantly as a NADPH-dependent oxoreductase (1Tomlinson J.W. Walker E.A. Bujalska I.J. Draper N. Lavery G.G. Cooper M.S. Hewison M. Stewart P.M. Endocr. Rev. 2004; 25: 831-866Crossref PubMed Scopus (841) Google Scholar). Independent of circulating glucocorticoid concentrations, the local generation of cortisol/corticosterone by 11β-HSD1 has emerged as an important factor in regulating hepatic glucose output (by augmenting gluconeogenesis) and visceral adiposity (by increasing adipocyte differentiation). Transgenic mice overexpressing 11β-HSD1 in liver and adipose tissue recapitulate features of the metabolic syndrome with visceral obesity, hepatic steatosis, glucose intolerance, insulin resistance, hyperlipidemia, and hypertension (3Masuzaki H. Paterson J. Shinyama H. Morton N.M. Mullins J.J. Seckl J.R. Flier J.S. Science. 2001; 294: 2166-2170Crossref PubMed Scopus (1527) Google Scholar, 4Masuzaki H. Yamamoto H. Kenyon C.J. Elmquist J.K. Morton N.M. Paterson J.M. Shinyama H. Sharp M.G. Fleming S. Mullins J.J. Seckl J.R. Flier J.S. J. Clin. Investig. 2003; 112: 83-90Crossref PubMed Scopus (383) Google Scholar, 5Paterson J.M. Morton N.M. Fievet C. Kenyon C.J. Holmes M.C. Staels B. Seckl J.R. Mullins J.J. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 7088-7093Crossref PubMed Scopus (394) Google Scholar). In contrast, knock-out (KO) mice lacking 11β-HSD1 show improved glucose tolerance, enhanced insulin sensitivity, and reduced weight gain when fed a high fat diet (6Kotelevtsev Y. Holmes M.C. Burchell A. Houston P.M. Schmoll D. Jamieson P. Best R. Brown R. Edwards C.R. Seckl J.R. Mullins J.J. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 14924-14929Crossref PubMed Scopus (812) Google Scholar, 7Morton N.M. Holmes M.C. Fievet C. Staels B. Tailleux A. Mullins J.J. Seckl J.R. J. Biol. Chem. 2001; 276: 41293-41300Abstract Full Text Full Text PDF PubMed Scopus (392) Google Scholar). 11β-HSD1 has therefore emerged as a novel therapeutic target to treat patients with obesity and insulin resistance. Indeed, selective 11β-HSD1 inhibitors improve glucose tolerance in diabetic mice (8Alberts P. Engblom L. Edling N. Forsgren M. Klingstrom G. Larsson C. Ronquist-Nii Y. Ohman B. Abrahmsen L. Diabetologia. 2002; 45: 1528-1532Crossref PubMed Scopus (254) Google Scholar, 9Alberts P. Nilsson C. Selen G. Engblom L.O. Edling N.H. Norling S. Klingstrom G. Larsson C. Forsgren M. Ashkzari M. Nilsson C.E. Fiedler M. Bergqvist E. Ohman B. Bjorkstrand E. Abrahmsen L.B. Endocrinology. 2003; 144: 4755-4762Crossref PubMed Scopus (249) Google Scholar, 10Barf T. Vallgarda J. Emond R. Haggstrom C. Kurz G. Nygren A. Larwood V. Mosialou E. Axelsson K. Olsson R. Engblom L. Edling N. Ronquist-Nii Y. Ohman B. Alberts P. Abrahmsen L. J. Med. Chem. 2002; 45: 3813-3815Crossref PubMed Scopus (225) Google Scholar). These in vivo findings are dependent upon the oxoreductase activity of 11β-HSD1, which is puzzling because activity studies performed on the purified 11β-HSD1 enzyme or on cell/tissue homogenates indicate almost exclusive unidirectional dehydrogenase activity (11Walker E.A. Clark A.M. Hewison M. Ride J.P. Stewart P.M. J. Biol. Chem. 2001; 276: 21343-21350Abstract Full Text Full Text PDF PubMed Scopus (66) Google Scholar). We hypothesized that the enzyme hexose-6-phosphate dehydrogenase (Hex-6-PDH) is a key factor in conferring oxoreductase activity upon 11β-HSD1. Hex-6-PDH is a bifunctional enzyme that catalyzes the first two steps of an endoluminal pentose phosphate pathway (12Mason P.J. Stevens D. Diez A. Knight S.W. Scopes D.A. Vulliamy T.J. Blood Cells Mol. Dis. 1999; 25: 30-37Crossref PubMed Scopus (45) Google Scholar) but is distinct from its cytosolic homologue, glucose-6-phosphate dehydrogenase, in being localized exclusively to the endoplasmic reticulum (ER) lumen. Hex-6-PDH has broad substrate specificity, accepting a variety of hexose 6-phosphates (13Beutler E. Morrison M. J. Biol. Chem. 1967; 242: 5289-5293Abstract Full Text PDF PubMed Google Scholar, 14Romanelli A. St Denis J.F. Vidal H. Tchu S. van de W.G. Biochem. Biophys. Res. Commun. 1994; 200: 1491-1497Crossref PubMed Scopus (25) Google Scholar) and has dual specificity for NAD+ and NADP+. However, under physiological conditions, the substrates within the ER are thought to be glucose 6-phosphate (Glc-6-P) and NADP+. Supply of Glc-6-P is ensured by the glucose 6-phosphate-transporter of the ER, but because the ER membrane is relatively impermeable to pyridine nucleotides, supply of NADP+ is maintained through a functional cooperation with endoluminal reductases such as 11β-HSD1. Rare patients have apparent cortisone reductase deficiency, with decreased urinary excretion of cortisol metabolites relative to those of cortisone. Affected females have increased adrenal androgen levels and a clinical presentation resembling polycystic ovarian syndrome. Although it has been proposed that cortisone reductase deficiency has a digenic etiology, requiring mutations in both the HSD11B1 and H6PD genes (1Tomlinson J.W. Walker E.A. Bujalska I.J. Draper N. Lavery G.G. Cooper M.S. Hewison M. Stewart P.M. Endocr. Rev. 2004; 25: 831-866Crossref PubMed Scopus (841) Google Scholar, 15Draper N. Walker E.A. Bujalska I.J. Tomlinson J.W. Chalder S.M. Arlt W. Lavery G.G. Bedendo O. Ray D.W. Laing I. Malunowicz E. White P.C. Hewison M. Mason P.J. Connell J.M. Shackleton C.H. Stewart P.M. Nat. Genet. 2003; 34: 434-439Crossref PubMed Scopus (255) Google Scholar), subsequent studies have demonstrated that polymorphisms in these genes are relatively common and are associated with neither abnormalities in urinary excretion nor an increased risk of polycystic ovarian syndrome (16San Millan J.L. Botella-Carretero J.I. Alvarez-Blasco F. Luque-Ramirez M. Sancho J. Moghetti P. Escobar-Morreale H.F. J. Clin. Endocrinol. Metab. 2005; 90: 4157-4162Crossref PubMed Scopus (58) Google Scholar, 17White P.C. J. Clin. Endocrinol. Metab. 2005; 90: 5880-5883Crossref PubMed Scopus (42) Google Scholar). Subsequently, a series of in vitro studies have demonstrated close cooperativity between 11β-HSD1 and Hex-6-PDH in preparations of rat liver microsomes with manipulation of Hex-6-PDH expression directly altering the set point of 11β-HSD1 activity (18Atanasov A.G. Nashev L.G. Schweizer R.A. Frick C. Odermatt A. FEBS Lett. 2004; 571: 129-133Crossref PubMed Scopus (192) Google Scholar, 19Banhegyi G. Benedetti A. Fulceri R. Senesi S. J. Biol. Chem. 2004; 279: 27017-27021Abstract Full Text Full Text PDF PubMed Scopus (152) Google Scholar, 20Bujalska I.J. Draper N. Michailidou Z. Tomlinson J.W. White P.C. Chapman K.E. Walker E.A. Stewart P.M. J. Mol. Endocrinol. 2005; 34: 675-684Crossref PubMed Scopus (146) Google Scholar, 21McCormick K.L. Wang X. Mick G.J. J. Biol. Chem. 2006; 281: 341-347Abstract Full Text Full Text PDF PubMed Scopus (66) Google Scholar). To date, however, little direct in vivo evidence exists as to the effects of Hex-6-PDH upon 11β-HSD1 activity. Here, through targeted gene inactivation in mice, we demonstrate that Hex-6-PDH inactivation profoundly affects 11β-HSD1 enzyme activity. Reagents—Glucose 6-sulfate, Glc-6-P, NADP+, NADPH, Triton X-100, corticosterone, and 11-dehydrocorticosterone were purchased from Sigma-Aldrich. All restriction enzymes and materials used for conventional cloning methodologies were purchased from New England Biolabs (Ipswich, MA). Tritiated corticosterone (specific activity, 1 mCi/ml) was purchased from Amersham Biosciences and used to generate radiolabeled 11-DHC as described (22Agarwal A.K. Tusie-Luna M.T. Monder C. White P.C. Mol. Endocrinol. 1990; 4: 1827-1832Crossref PubMed Scopus (164) Google Scholar). Design—All animal experiments had the approval of the Institutional Animal Care and Use Committee and were performed according to procedures approved by that committee. Mice were housed in standard conditions on a 12-h light/12-h dark cycle with access to standard rodent chow and water ad libitum. Generation of a Targeted H6PD Gene—The murine H6PD gene spans ∼15 kb and contains 5 exons. Genomic DNA from 129SvJ embryonic stem cells was used to amplify 5.5-kb 5′ and 2-kb 3′ homology arms, which were subsequently cloned into pBluescript SK(+) containing both PGK-Neo and thymidine kinase cassettes. The targeting vector was designed to replace exons 2 and 3. Following verification by DNA sequencing, the construct was linearized with SacII and electroporated into E14TG2a mouse embryonic stem cells. Southern hybridization of NcoI-digested genomic DNA probed with a 500-bp H6PD fragment located at the 5′ and 3′ ends of the targeting vector identified cells positive for a recombined H6PD locus after selection in G418 and gancyclovir. Three targeted embryonic stem cell clones were expanded, screened with Neo and 3′ probes, and karyotyped to ensure correct recombination and chromosomal integrity. Two clones were injected into C57BL/6 blastocysts to produce chimeric mice. Chimeric mice derived from embryonic stem cell clone were mated with C57BL/6 females to achieve germ line transmission of the mutant allele. From these, heterozygote mice were intercrossed to generate WT, heterozygote and KO mice. Genotypes were routinely monitored using PCR and Southern blotting. For blotting, DNA was extracted from tail biopsy, digested with NcoI, and probed with the 3′ probe as above. For genotyping the following primers were multiplexed in a standard PCR reaction: P1, 5′-CTTGTCACTCTGTCTGTCACTGTGG-3′; P2, 5′-ACCATGTGGCCTTGTGCCTG-3′; P3, 5′-CTATGGCTTCTGAGGCGGAAAG-3′. Microsome Preparation—WT and KO liver microsomes were prepared from 13-16-week-old male mice, resuspended in MOPS buffer (100 mm KCl, 20 mm NaCl, 1 mm MgCl2 and 20 mm MOPS, pH 7.2), aliquoted, and rapidly frozen in liquid nitrogen prior to long term storage. The integrity of the microsomes was determined using the mannose-6-phosphatase assay and was >90% in all preparations. Protein concentration of the microsomes was established using the Bio-Rad protein assay. Immunoblotting—SDS-PAGE was performed by the method of Laemmli (23Laemmli U.K. Nature. 1970; 227: 680-685Crossref PubMed Scopus (207139) Google Scholar) with 2.5 and 5 μg of mouse microsomal liver protein on 10% acrylamide minigels using a Bio-Rad Mini-Protean II apparatus. Following electrophoresis, proteins were transferred to Immobilon-P membrane (Millipore Corp., Bedford, MA). Nonspecific protein binding was blocked by incubating membranes in 20% nonfat milk, 0.1% Tween 20 in phosphate-buffered saline at 25 °C for 1 h. Membranes were then incubated with a polyclonal antibody to human Hex-6-PDH at a dilution of 1:500 for 16 h at 4 °C. Following three 10-min washes in phosphate-buffered saline, 0.1% Tween 20, membranes were incubated with secondary antibody (goat anti-rabbit IgG peroxidase conjugate (Dako, Glostrup, Denmark) at a dilution of 1:10,000 for 1.5 h at room temperature. Bound peroxidase-conjugated IgG was visualized using an ECL detection kit (Amersham Biosciences) and exposing membranes to x-ray film (Kodak). Enzyme Assays—Hex-6-PDH enzyme activity was measured by spectrophotometric detection of NADPH using absorbance readings taken at 340 nm using an Ultrospec 2100pro spectrophotometer (Amersham Biosciences). Microsomes were with Triton and incubated in MOPS pH at °C in the of 1 mm of the substrate glucose and mm NADP+. readings were taken at for 5 11β-HSD1 oxoreductase and dehydrogenase were measured using both and Microsomes were incubated at °C for 20 in MOPS buffer in the of 2 to of and the Hex-6-PDH substrate Glc-6-P at 1 All experiments were performed in of was on in the metabolic and were from of KO and KO male The was and with water being and The water were to described C.H. J. Biochem. Mol. Biol. 45: PubMed Scopus Google Scholar, A.M. C. and in New Scholar). In the was by using The were to conjugate using from and were extracted by experiments that the were and for were purified by using and a Three were for corticosterone Following the of as an and of the were prepared prior to The were by on a metabolites were identified through of their were by the on the to the of the we had on were as a of the corticosterone metabolites (22Agarwal A.K. Tusie-Luna M.T. Monder C. White P.C. Mol. Endocrinol. 1990; 4: 1827-1832Crossref PubMed Scopus (164) Google Scholar, U.K. Nature. 1970; 227: 680-685Crossref PubMed Scopus (207139) Google Scholar). Blood 20 both KO and mice a and was for levels in were measured between and using a method were performed using are expressed as with as of was to between KO and mice. of the H6PD was in the murine H6PD gene through of exons 2 and with a recombination was in of clones screened by Southern blotting, and correct targeting was with Southern using the 5′ and KO mice were and maintained through of 129SvJ and C57BL/6 heterozygote mice and by Southern using the 3′ probe Mice were by PCR using DNA extracted from tail P1, P2, and were used in a PCR to rapidly WT, KO, and heterozygote mice. and were in heterozygote with genotyping of from a of abnormalities were in KO mice at Mice Hex-6-PDH Protein and that Hex-6-PDH protein be in KO liver microsomes Hex-6-PDH enzyme activity in and KO mice was using glucose as a substrate for murine Hex-6-PDH J.L. Mason P.J. Biochem. Biophys. 2003; PubMed Scopus Google Scholar). Hex-6-PDH activity was in KO mice with nm in mice and nm in mice. of 11β-HSD1 in Hex-6-PDH KO enzyme was by the oxoreductase and dehydrogenase in liver microsomes from and KO mice in the or of Glc-6-P, the substrate for Hex-6-PDH In the of Glc-6-P, microsomes from mice conversion of 11-DHC to corticosterone and conversion of corticosterone to 11-DHC In the of Glc-6-P, conversion of 11-DHC to corticosterone increased to in mice. By contrast, liver microsomes from KO mice conversion of 11-DHC to corticosterone, with or Glc-6-P, of 11β-HSD1 oxoreductase activity This in oxoreductase activity in KO was by an increase in dehydrogenase activity of corticosterone to 11-DHC in KO in a from oxoreductase to dehydrogenase activity in the of of microsomes with resulted in a of conversion of 11-DHC to corticosterone of substrate for Hex-6-PDH (Glc-6-P) was or Glc-6-P, with the requirement for microsomes and a between Hex-6-PDH and 11β-HSD1 in the ER to ensure activity. of 11β-HSD1 activity in vivo was through of metabolites from from male and mice 5 in and and 11-DHC metabolites were in mouse These were the with to be The of the and metabolites was and the were mice almost exclusively with an and of 11-DHC metabolites were the in the KO mice were 11-DHC In male mice the of 11-DHC metabolites to corticosterone metabolites was increasing to in the KO In mice the was increasing to in KO expressed as a of 11-DHC metabolites in the of and KO the the lack of oxoreductase activity in KO mice adrenal of male KO mice fed a chow were with mice In corticosterone levels were in KO mice in mice Our show that the inactivation of the murine H6PD gene the of 11β-HSD1. In but microsomal was oxoreductase activity and dehydrogenase activity. However, upon of Glc-6-P substrate for oxoreductase activity was dehydrogenase activity was of the this of reductase activity by Glc-6-P was because of the of an between 11β-HSD1 and Hex-6-PDH 11β-HSD1 is to the ER membrane A. P. A. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar), Hex-6-PDH is within the ER J. Proc. Natl. Acad. Sci. U. S. A. 90: PubMed Scopus Google Scholar). studies are to define the between these two proteins within the ER lumen. By contrast, hepatic microsomes from Hex-6-PDH KO mice show oxoreductase that be with the of have dehydrogenase activity, that in vivo these mice have a in hepatic 11β-HSD1 enzyme activity in the liver from oxoreductase to dehydrogenase. in vivo of corticosterone through urinary these in vitro In the of to is an of activity (1Tomlinson J.W. Walker E.A. Bujalska I.J. Draper N. Lavery G.G. Cooper M.S. Hewison M. Stewart P.M. Endocr. Rev. 2004; 25: 831-866Crossref PubMed Scopus (841) Google Scholar, P.C. Mune T. Agarwal A.K. Endocr. Rev. 1997; 18: 135-156Crossref PubMed Scopus (542) Google Scholar). Here, using a the of 11-dehydrocorticosterone to corticosterone metabolites between and KO mice. on the urinary 11-DHC the set point of 11β-HSD1 was in of corticosterone in mice oxoreductase but this was in KO mice. these are consistent with (18Atanasov A.G. Nashev L.G. Schweizer R.A. Frick C. Odermatt A. FEBS Lett. 2004; 571: 129-133Crossref PubMed Scopus (192) Google Scholar, 19Banhegyi G. Benedetti A. Fulceri R. Senesi S. J. Biol. Chem. 2004; 279: 27017-27021Abstract Full Text Full Text PDF PubMed Scopus (152) Google Scholar, 20Bujalska I.J. Draper N. Michailidou Z. Tomlinson J.W. White P.C. Chapman K.E. Walker E.A. Stewart P.M. J. Mol. Endocrinol. 2005; 34: 675-684Crossref PubMed Scopus (146) Google Scholar, I. E. FEBS Lett. 2002; PubMed Scopus Google Scholar) and demonstrate directly for the first that Glc-6-P within the ER the substrate for Hex-6-PDH and of NADPH for the generation of active glucocorticoid this within In the Hex-6-PDH KO mice, circulating corticosterone levels were with the adrenal This is in to the from the 11β-HSD1 KO mice (6Kotelevtsev Y. Holmes M.C. Burchell A. Houston P.M. Schmoll D. Jamieson P. Best R. Brown R. Edwards C.R. Seckl J.R. Mullins J.J. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 14924-14929Crossref PubMed Scopus (812) Google Scholar) corticosterone levels were in KO in mice when measured at a point the 11β-HSD1 KO mice, however, the activity of 11β-HSD1 in the Hex-6-PDH mice the of oxoreductase activity but a increase in its dehydrogenase activity. It to be this in activity for in the of the between these mice. Our has upon to be a between Hex-6-PDH and 11β-HSD1, in However, Hex-6-PDH is expressed in the adrenal and K. J. PubMed Scopus Google Scholar, B. E. Biochem. Biophys. 1970; PubMed Scopus Google Scholar). an we have been unable to endoluminal but it is that these and be of these mice is to define the of lack of glucocorticoid generation in liver and adipose tissue upon glucose tolerance and adiposity but to the of of ER in key In these of the and of 11β-HSD1, that NADPH-dependent oxoreductase activity is dependent on the activity of the enzyme Mice lacking Hex-6-PDH have a in 11β-HSD1 activity from oxoreductase to dehydrogenase, activation to is in the of activity in the of the metabolic with selective 11β-HSD1 inhibitors improved glucose tolerance and weight reduction in mouse of obesity (8Alberts P. Engblom L. Edling N. Forsgren M. Klingstrom G. Larsson C. Ronquist-Nii Y. Ohman B. Abrahmsen L. Diabetologia. 2002; 45: 1528-1532Crossref PubMed Scopus (254) Google Scholar, 9Alberts P. Nilsson C. Selen G. Engblom L.O. Edling N.H. Norling S. Klingstrom G. Larsson C. Forsgren M. Ashkzari M. Nilsson C.E. Fiedler M. Bergqvist E. Ohman B. Bjorkstrand E. Abrahmsen L.B. Endocrinology. 2003; 144: 4755-4762Crossref PubMed Scopus (249) Google Scholar). Our findings add a new to this pathway but define a novel pathway that the ER and We and for in the H6PD and Ride for

References

27